Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis
Mohapradeep Mohan, Benjamin I. Perry, Ponnusamy Saravanan, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
Marc D. Binder, Victor Mazereel, Marc Stroobants, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 57
A proteome-scale map of the SARS-CoV-2–human contactome
Dae‐Kyum Kim, Benjamin Weller, Chung-Wen Lin, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 1, pp. 140-149
Open Access | Times Cited: 47
Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression
Engelberta Pardamean, Waskita Roan, Karina Terry Amartini Iskandar, et al.
General Hospital Psychiatry (2022) Vol. 75, pp. 61-67
Open Access | Times Cited: 30
Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function
Qi Zhou, Jiayi Li, Jiahui Zhu, et al.
Brain Behavior & Immunity - Health (2025), pp. 100997-100997
Open Access
Treatment of Cognitive Impairment Associated with Schizophrenia Spectrum Disorders: New Evidence, Challenges, and Future Perspectives
Irene Calzavara‐Pinton, Gabriele Nibbio, Sergio Barlati, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 791-791
Open Access | Times Cited: 3
Medium-term and peri-lockdown course of psychosocial burden during the ongoing COVID-19 pandemic: a longitudinal study on patients with pre-existing mental disorders
Claudia Bartels, Philipp Heßmann, Ulrike Schmidt, et al.
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 272, Iss. 5, pp. 757-771
Open Access | Times Cited: 22
The role of psychological autopsy in investigating a case of atypical suicide in schizophrenia: a case report with a brief review of literature
Roxana-Mihaela Crișan, Ciprian Băcilă, Silviu Morar
Egyptian Journal of Forensic Sciences (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Psychosocial Effects of the COVID-19 Pandemic on Patients With Schizophrenia and Their Caregivers
Alejandra Caqueo‐Urízar, Alfonso Urzúa, Felipe Ponce, et al.
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 16
Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis
Jing Xia, Shuhan Chen, Yaping Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting
Sergio Barlati, Gabriele Nibbio, Francesco Paolo Bianchi, et al.
Psychiatry Research (2022) Vol. 317, pp. 114878-114878
Open Access | Times Cited: 9
Increased COVID-19 mortality in patients with schizophrenia: A retrospective study in Brazil
Diogo Fernando Bornancin Costa, Paula Rossignoli, Deise Regina Sprada Pontarolli, et al.
Schizophrenia Research (2024) Vol. 271, pp. 200-205
Closed Access | Times Cited: 1
Causes and countermeasures for the increased infection and COVID-19 mortality rates in patients with schizophrenia
Zhen-Ying Li, Yuqian Li, Jingru Zhou, et al.
IBRO Neuroscience Reports (2024) Vol. 17, pp. 456-462
Open Access | Times Cited: 1
Attitudes toward COVID-19 pandemic measures and clinical symptom severity in schizophrenia patients: a preliminary cross-sectional study
Onur Durmaz, Haluk Usta, Batuhan Ayık, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 9
Open Access | Times Cited: 3
Changes in Quality of Life in Treatment-Resistant Schizophrenia Patients Undergoing Avatar Therapy: A Content Analysis
Mélissa Beaudoin, Stéphane Potvin, Kingsada Phraxayavong, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 522-522
Open Access | Times Cited: 2
COVID-19 mortality among veterans with serious mental illness in the veterans health administration
Nicholas W. Bowersox, Julia Browne, Peter P. Grau, et al.
Journal of Psychiatric Research (2023) Vol. 163, pp. 222-229
Open Access | Times Cited: 2
“You Have No Idea How Much ‘Just Get the Shot’ Is Triggering Me”: Experiences of COVID-19 Vaccination in Individuals with Psychosis and Schizophrenia
Minna Lyons, Gayle Brewer
Social Sciences (2023) Vol. 12, Iss. 6, pp. 361-361
Open Access | Times Cited: 2
Eugenics, Admixture, and Multiculturalism in Twentieth-Century Northern Sweden: Contesting Disability and Sámi Genocide
Terry-Lee Marttinen
Journal of Critical Mixed Race Studies (2022) Vol. 1, Iss. 2
Open Access | Times Cited: 4
Psychiatric symptoms before and after COVID-19 vaccination: A cohort study of hospitalized schizophrenia patients
Feng Jia, Cuizhu Dong, Hong Guo, et al.
Asian Journal of Psychiatry (2022) Vol. 78, pp. 103319-103319
Open Access | Times Cited: 4
New modified mesoporous silica nanoparticles with bimetallic Ni-Zr for electroanalytical detection of dopamine
Mohamad Rafizie Aiman Mohamed Roduan, Mohamad Idris Saidin, S.M. Sidik, et al.
Journal of Electrochemical Science and Engineering (2022)
Open Access | Times Cited: 3
Systematic discovery of virus-perturbed molecular pathways linking to schizophrenia
Guanmei Liang, Wenjuan Yi, Yanjun Li, et al.
The Innovation Medicine (2024) Vol. 2, Iss. 2, pp. 100062-100062
Open Access
Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
Tiffany Dyu, Char Leung, Ana Cristina Simões e Silva
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Global research in schizophrenia and serotonin: a bibliometric analysis
Gustavo Canul-Medina, Gael López-Pech, Francisco Jiménez‐Trejo
Frontiers in Psychiatry (2024) Vol. 15
Open Access
The impact of COVID-19 vaccination on psychiatric symptoms in schizophrenia patients: A retrospective study
Xinghu Wu, Yu Gao, Bisheng Cheng, et al.
Medicine (2023) Vol. 102, Iss. 23, pp. e34016-e34016
Open Access | Times Cited: 1
Comparison of attitudes toward the coronavirus disease vaccine, fear of coronavirus disease, and perception regarding causes of coronavirus disease between patients with serious mental illness and healthy controls
Ayse Gökçen Gündoğmuş, Selma Ercan Doğu, Gamze Zengin İspir
Journal of Public Health (2023)
Closed Access | Times Cited: 1
Probing the Neuro-psychological Changes Observed with the Administration of COVID-19 Drugs
Indranath Chatterjee, Videsha Bansal
Current Topics in Medicinal Chemistry (2022) Vol. 23, Iss. 2, pp. 143-154
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top